Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030567 (Parkinson's disease)
 63,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In order to investigate emaciation in patients with Parkinson's disease (PD), an anthropometric study was undertaken. In 59 out-patients (29 males, 30 females) with PD, the changes in body weight (delta BW) and in body mass index (delta BMI) were obtained and the ratio of body fat (% Fat) was measured with a bioelectrical impedance method. Twenty-two percent of the patients with PD had lost more than 10 Kg of BW (7% of males, 37% of females) and delta BW was -3.9 +/- 7.1 Kg, delta BMI -1.8 +/- 3.2 Kg/m2, and %Fat 25.9 +/- 5.6%. The reductions in both the BW and BMI of females with PD were significantly higher than for males (p < 0.003, p < 0.001, respectively). The disease duration had no correlation with delta BW or delta BMI, but a significant negative correlation with %Fat (all: p < 0.05; females: p < 0.03). However, no correlation was found between delta BW, delta BMI or %Fat on the one hand, and the disease severity or the total dosage of L-dopa with carbidopa on the other. We conclude that patients with PD, especially in females, experience gradual body fat loss according to disease duration.
 ...
PMID:[Body fat loss in patients with Parkinson's disease]. 939 58

We used only dexmedetomidine to sedate a patient with Alzheimer disease, Parkinson's syndrome and emaciation for decubitus treatment in the prone position. The infusion rate of dexmedetomidine without a loading dose was increased until sufficient sedation was attained. The maximum plasma concentration and the plasma concentration in a stable state, which were calculated by pharmacokinetic simulation analysis, were 2.3 ng x ml(-1) and 1.5 ng x ml(-1), respectively. Respiration disorder did not occur and hemodynamic stability was preserved despite administration up to 11.5 mcg x kg(-1) x h(-1). An increase in the dose per weight was needed to increase the absolute dose because of emaciation. It was found by pharmacokinetic simulation analysis that the plasma concentration of dexmedetomidine required for decubitus treatment might be higher than the plasma concentration considered to be necessary for sedation in intensive care units. The simulation was conducted to administer dexmedetomidine, to estimate hemodynamic reaction, and to estimate the necessary plasma concentration. We conclude that dexmedetomidine is useful as an anesthetic agent for decubitus treatment in the prone position, although further investigations with regard to its safety are required.
 ...
PMID:[Pharmacokinetic simulation of high-dose administration of dexmedetomidine for decubitus treatment]. 1691 Apr 81